Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma
Julius C. Enßle, Julia Campe, Sarah Büchel, et al.
Cancer Cell (2022) Vol. 40, Iss. 6, pp. 587-589
Open Access | Times Cited: 23

Showing 23 citing articles:

Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
Evangelos Terpos, Pellegrino Musto, Monika Engelhardt, et al.
Leukemia (2023) Vol. 37, Iss. 6, pp. 1175-1185
Open Access | Times Cited: 33
Mannan-Decorated Lipid Calcium Phosphate Nanoparticle Vaccine Increased the Antitumor Immune Response by Modulating the Tumor Microenvironment
Liusheng Wu, Lei Yang, Xinye Qian, et al.
Journal of Functional Biomaterials (2024) Vol. 15, Iss. 8, pp. 229-229
Open Access | Times Cited: 5
Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections
Maryam I. Azeem, Ajay K. Nooka, Uma Shanmugasundaram, et al.
Blood Cancer Discovery (2022) Vol. 4, Iss. 2, pp. 106-117
Open Access | Times Cited: 26
Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy
Ioannis Ntanasis‐Stathopoulos, Vangelis Karalis, Maria Gavriatopoulou, et al.
HemaSphere (2022) Vol. 6, Iss. 8, pp. e764-e764
Open Access | Times Cited: 25
Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma
Andrea Keppler‐Hafkemeyer, Christine Greil, Paul R. Wratil, et al.
Nature Cancer (2022)
Open Access | Times Cited: 23
Breakthrough Infections in SARS-CoV-2-Vaccinated Multiple Myeloma Patients Improve Cross-Protection against Omicron Variants
Angelika Wagner, Erika Garner‐Spitzer, Claudia Auer, et al.
Vaccines (2024) Vol. 12, Iss. 5, pp. 518-518
Open Access | Times Cited: 4
COVID-19 Vaccines against Omicron Variant: Real-World Data on Effectiveness
Yousra Kherabi, Odile Launay, Liêm Binh Luong Nguyen
Viruses (2022) Vol. 14, Iss. 10, pp. 2086-2086
Open Access | Times Cited: 18
Low Spike Antibody Levels and Impaired BA.4/5 Neutralization in Patients with Multiple Myeloma or Waldenstrom’s Macroglobulinemia after BNT162b2 Booster Vaccination
Margherita Rosati, Evangelos Terpos, Jenifer Bear, et al.
Cancers (2022) Vol. 14, Iss. 23, pp. 5816-5816
Open Access | Times Cited: 16
Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis
Εfstathia Liatsou, Ioannis Ntanasis‐Stathopoulos, Stavros Lykos, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2266-2266
Open Access | Times Cited: 10
Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry
Pellegrino Musto, Jon Salmanton‐García, Nicola Sgherza, et al.
Hematological Oncology (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 9
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma
Katia Mancuso, Elena Zamagni, Vincenza Solli, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 6
Humoral and cellular responses to SARS‐CoV‐2 in patients with B‐cell haematological malignancies improve with successive vaccination
Christopher L. Pinder, Dylan Jankovic, Thomas A. Fox, et al.
British Journal of Haematology (2023) Vol. 202, Iss. 6, pp. 1091-1103
Open Access | Times Cited: 5
Immune Reconstitution and Vaccinations in Multiple Myeloma: A Report From the 19th International Myeloma Society Annual Workshop
Evangelos Terpos, Paola Neri, Niels W.C.J. van de Donk, et al.
Clinical Lymphoma Myeloma & Leukemia (2023) Vol. 23, Iss. 6, pp. 413-419
Closed Access | Times Cited: 4
Examining the immunological responses to COVID-19 vaccination in multiple myeloma patients: a systematic review and meta-analysis
Hamid Harandi, Parisa Fallahtafti, Amirali Karimi, et al.
BMC Geriatrics (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Humoral and cellular immune responses after three or four doses of BNT162b2 in patients with hematological malignancies
Line Dam Heftdal, Sebastian Rask Hamm, Laura Pérez‐Alós, et al.
European Journal Of Haematology (2023) Vol. 111, Iss. 2, pp. 229-239
Open Access | Times Cited: 3
Cytokine-responsive T- and NK-cells portray SARS-CoV-2 vaccine-responders and infection in multiple myeloma patients
Julius C. Enßle, Julia Campe, Alina Moter, et al.
Leukemia (2023) Vol. 38, Iss. 1, pp. 168-180
Open Access | Times Cited: 3
COVID-19 vaccine immune response in patients with plasma cell dyscrasia: a systematic review
Unaiza Faizan, Lakshmi G. Nair, Maroun Bou Zerdan, et al.
Therapeutic Advances in Vaccines and Immunotherapy (2023) Vol. 11
Open Access | Times Cited: 2
Dynamics of humoral and cellular response to three doses of anti-SARS-CoV-2 BNT162b2 vaccine in patients with hematological malignancies and older subjects
Valentina Laquintana, Carla Mottini, Francesco Marchesi, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access
Blood Disorders: Response and Achille Heel in the Framework of SARS-Cov-2- a Short Review
Maria Giovanna Buonomenna
Elsevier eBooks (2024), pp. 455-466
Closed Access
Impaired acute‐phase humoral immunity is the major factor predicting unfavorable outcomes in multiple myeloma patients with SARS‐CoV‐2 Omicron variants outbreak infection
Ziping Li, Huiwen He, Haolong Li, et al.
International Journal of Cancer (2024) Vol. 155, Iss. 8, pp. 1500-1509
Closed Access
Defective Immunity Against SARS-CoV-2 Omicron Variants Despite Full Vaccination in Hematologic Malignancies
Laurence Zitvogel, Lisa Derosa, Guido Kroemer
Blood Cancer Discovery (2023) Vol. 4, Iss. 3, pp. 172-175
Open Access | Times Cited: 1
Data from Impaired SARS-CoV-2 Variant Neutralization and CD8<sup>+</sup> T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections
Maryam I. Azeem, Ajay K. Nooka, Uma Shanmugasundaram, et al.
(2023)
Open Access
Humoral and cellular BNT162b2 mRNA-based booster vaccine-induced immunity in patients with multiple myeloma and persistence of neutralising antibodies: results of a prospective single-centre cohort study
Tobias Silzle, Christian R. Kahlert, Werner C. Albrich, et al.
Schweizerische medizinische Wochenschrift (2023) Vol. 153, Iss. 6, pp. 40090-40090
Open Access
Page 1

Scroll to top